BR112022021077A2 - Anticorpos humanizados antifator bb de complemento e uso dos mesmos - Google Patents

Anticorpos humanizados antifator bb de complemento e uso dos mesmos

Info

Publication number
BR112022021077A2
BR112022021077A2 BR112022021077A BR112022021077A BR112022021077A2 BR 112022021077 A2 BR112022021077 A2 BR 112022021077A2 BR 112022021077 A BR112022021077 A BR 112022021077A BR 112022021077 A BR112022021077 A BR 112022021077A BR 112022021077 A2 BR112022021077 A2 BR 112022021077A2
Authority
BR
Brazil
Prior art keywords
complement
humanized antibodies
factor
antibodies
factor humanized
Prior art date
Application number
BR112022021077A
Other languages
English (en)
Inventor
Parry Graham
Moore Stephen
Storek Michael
C Leksa Nina
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112022021077A2 publication Critical patent/BR112022021077A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICORPOS HUMANIZADOS ANTIFATOR BB DE COMPLEMENTO E USO DOS MESMOS. A presente invenção refere-se a anticorpos humanizados antifator Bb, métodos de produção dos anticorpos e métodos de uso dos anticorpos.
BR112022021077A 2020-04-20 2021-04-19 Anticorpos humanizados antifator bb de complemento e uso dos mesmos BR112022021077A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012590P 2020-04-20 2020-04-20
PCT/US2021/027981 WO2021216458A1 (en) 2020-04-20 2021-04-19 Humanized anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022021077A2 true BR112022021077A2 (pt) 2022-12-13

Family

ID=78221896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021077A BR112022021077A2 (pt) 2020-04-20 2021-04-19 Anticorpos humanizados antifator bb de complemento e uso dos mesmos

Country Status (14)

Country Link
US (2) US11242382B2 (pt)
EP (1) EP4139350A4 (pt)
JP (1) JP2023522102A (pt)
KR (1) KR20230004686A (pt)
CN (1) CN115702165A (pt)
AR (1) AR121881A1 (pt)
AU (1) AU2021261257A1 (pt)
BR (1) BR112022021077A2 (pt)
CA (1) CA3173325A1 (pt)
CO (1) CO2022014878A2 (pt)
IL (1) IL297444A (pt)
MX (1) MX2022013135A (pt)
TW (1) TW202140543A (pt)
WO (1) WO2021216458A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180529A (es) 2016-04-04 2019-03-21 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
PL1737891T3 (pl) * 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
NZ616992A (en) 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
EP2195024B1 (en) 2007-08-27 2016-10-05 NovelMed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
AU2008323939A1 (en) 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor B antibodies and their uses
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CA2853719A1 (en) * 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
WO2013152020A1 (en) 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3110845A1 (en) 2014-02-27 2017-01-04 Allergan, Inc. Complement factor bb antibodies
US10513558B2 (en) * 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CR20180529A (es) 2016-04-04 2019-03-21 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
TWI773695B (zh) 2016-10-12 2022-08-11 美商生物維瑞提夫美國公司 抗Ｃ１ｓ抗體及其使用方法
CN111527105A (zh) 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Also Published As

Publication number Publication date
TW202140543A (zh) 2021-11-01
CN115702165A (zh) 2023-02-14
CA3173325A1 (en) 2021-10-28
US11999780B2 (en) 2024-06-04
AR121881A1 (es) 2022-07-20
IL297444A (en) 2022-12-01
MX2022013135A (es) 2022-11-10
US20210332115A1 (en) 2021-10-28
EP4139350A4 (en) 2024-04-24
AU2021261257A1 (en) 2022-12-22
EP4139350A1 (en) 2023-03-01
US11242382B2 (en) 2022-02-08
JP2023522102A (ja) 2023-05-26
KR20230004686A (ko) 2023-01-06
WO2021216458A1 (en) 2021-10-28
CO2022014878A2 (es) 2023-02-16
US20220213179A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
MY186351A (en) Multispecific antibodies
EA201791270A1 (ru) Модифицированные april-связывающие антитела
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
BR112021020357A2 (pt) Anticorpos anti-cd3 de alta afinidade e métodos para sua geração e uso
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2021015254A2 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
BR112022015902A2 (pt) Anticorpos de cd19 anti-humanos
ZA202205288B (en) Humanized antibody and method for using the same
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
BR112023024837A2 (pt) Anticorpos anti-ccr8